Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes

European Journal of Clinical Pharmacology

Volumn 54, Issue 12, 1999, Pages 947-951

  Hemeryck, A ^a   De Vriendt, C ^a   Belpaire, F M ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

(S) warfarin; CYP2C9; SSRI

Indexed keywords

CYTOCHROME P450; SEROTONIN UPTAKE INHIBITOR; TOLBUTAMIDE; WARFARIN;

ARTICLE; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MICHAELIS CONSTANT; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; REACTION TIME;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUVOXAMINE; HUMANS; MICROSOMES, LIVER; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; STATISTICS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TIME FACTORS; TOLBUTAMIDE; WARFARIN;

EID: 0032965977     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050580     Document Type: Article

References (28)

1. Harvey AT, Preskorn SH (1996) Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 16: 345-355
2. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI (1997) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 44: 495-498
3. Levy RH (1995) Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 36 [Suppl 5]: S8-S13
4. Miners JO, Birkett DJ (1996) The use of tolbutamide as a substrate probe for human hepatic cytochrome P4502C9. Methods Enzymol 272: 139-145
5. Kaminsky LS, Zhang Z-Y (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73: 67-74
6. Benfield P, Ward A (1986) Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32: 313-334
7. Hanger HC, Thomas F (1995) Fluoxetine and warfarin interactions. N Z Med J 108: 157
8. Woolfrey S, Gammack NS, Dewar MS, Brown PJ (1993) Fluoxetine-warfarin interaction. BMJ 307: 241
9. Amar-Costesec A, Beaufay H, Wibo M, Thines-Sempoux D, Feytmans E, Robbi M, Berthet J (1974) Analytical study of microsomes and isolated subcellular membranes from rat liver. J Cell Biol 61: 201-212
10. Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein using the principle of protein-dye binding. Ann Clin Biochem 72: 248-252
11. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes. Biochem Pharmacol 37: 1137-1144
12. Lang D, Böker R (1995) Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr Biomed Sci Appl 672: 305-309
13. Bourrié M, Meunier V, Berger Y, Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277: 321-332
14. Rettie AE, Eddy AC, Heimark LD, Gibaldi M, Trager WF (1989) Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 17: 265-270
15. Yamazaki H, Shimada T (1997) Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol 54: 1195-1203
16. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M (1994) Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 56: 471-476
17. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: 73-78
18. Kobayashi K, Yamamote T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y (1995) The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 40: 481-485
19. Kunze KL, Eddy AC, Gibaldi M, Trager WF (1991) Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 3: 24-29
20. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214
21. Van Harten J (1993) Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 24: 203-220
22. Fleishaker JC, Hulst LK (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46: 35-39
23. Rowe H, Carmichael R, Lemberger L (1978) The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sci 23: 807-812
24. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JGC (1989) Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand 80: 102-106
25. Apseloff G, Wilner KD, Gerber N, Tremaine LM (1997) Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 32 [Suppl 1]: 37-42
26. Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE (1997) Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 44: 199-202
27. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR (1985) Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 46: 14-19
28. Tremaine LM, Wilner KD, Perskorn SH (1997) A study of the potential effect of sertraline on the pharmaokinetics and protein binding of tolbutamide. Clin Pharmacokinet 32 [Suppl 1]: 31-36